Compare Amgen, Inc. (AMGN) vs Vistra Corp (VST) Price & Performance

Amgen, Inc.Trade

Vistra CorpTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Vistra Corp — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while Vistra Corp trades at $145.82 (market cap $48.64B). The key difference: Amgen, Inc. is far larger — about 4.6× Vistra Corp's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.

	AMGN	VST
Market Cap	$224.14B	$48.64B
Sector	Health	Technology
52-Week High	$417.20	$217.92
52-Week Low	$271.18	$134.71
Enterprise Value	$267.45B	$70.58B
Dividend Yield	2.43%	0.63%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

No Aura AI signal available yet.

Vistra Corp

Vistra (VST) trades at $140.59, down 0.56% on the day, with a bearish technical signal driven by selling pressure in moving averages. The stock shows strong profitability with a net income margin of 11.55% and ROE of 75.73%, though recent quarterly EPS results were mixed with two misses against expectations. Analyst consensus remains overwhelmingly bullish with a 90.91% buy rating and a $239.75 price target, highlighting growth potential from data center electricity demand.

The outlook is supported by strategic positioning in power generation for AI infrastructure, but risks include volatile hedging impacts and high P/B valuation. Earnings growth from hyperscaler deals and nuclear assets offers upside, while technical weakness near support at $136 requires monitoring for stability.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

AMGN

BioCryst hits profitability with strong Q2 revenue, sparking takeover interest in rare disease biotech.24/7 Wall Street · 1 day agoBullish View details →

VST

Vistra Corp. holds steady as earnings rise but sales fall amid rising costs and strategic growth moves.Seeking Alpha · 4 days agoNeutral Vistra misses Q3 earnings estimates due to $472M hedge loss but core operations show strong 30% EBITDA growth.Gordon Thompson · 4 days agoNeutral View details →

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

About Vistra Corp

Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.